Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin
- 1 August 1980
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 18 (2) , 240-242
- https://doi.org/10.1128/aac.18.2.240
Abstract
The pharmacokinetics of the new cephalosporin Ro-13-9904 were studied in six healthy male volunteers receiving a 500-mg dose as a bolus intravenously. Tissue penetration of the antibiotic was estimated by using a cantharides blister method. The data obtained fitted a two-compartment open model. The mean elimination half-life was about 8 h, which is considerably longer than that of other beta-lactam compounds. The distribution volume was 4.3 liters in the central compartment. Levels of Ro 13-9904 in blister fluid exceeded those in serum after 6.5 h. Approximately 60% of the antibiotic was excreted in the urine.This publication has 7 references indexed in Scilit:
- The pharmacokinetics of LY127935, a broad spectrum oxa-β-lactamJournal of Antimicrobial Chemotherapy, 1980
- Antibacterial Activity of a New 1-Oxa Cephalosporin Compared with That of Other β-Lactam CompoundsAntimicrobial Agents and Chemotherapy, 1979
- Human Pharmacology of Cefotaxime (HR 756), a New CephalosporinAntimicrobial Agents and Chemotherapy, 1979
- Pharmacokinetics of Bay k 4999, a New Broad-Spectrum PenicillinAntimicrobial Agents and Chemotherapy, 1979
- Beta-Lactamase Stability of HR 756, a Novel Cephalosporin, Compared to That of Cefuroxime and CefoxitinAntimicrobial Agents and Chemotherapy, 1978
- Clinical PharmacokineticsNew England Journal of Medicine, 1975
- Cefazolin, ein neues Breitspektrum-AntibiotikumDeutsche Medizinische Wochenschrift (1946), 1973